Global Renal Cell Carcinoma Drugs Market 2020 - Product Image

Global Renal Cell Carcinoma Drugs Market 2020

  • ID: 3618301
  • Report
  • Region: Global
  • 65 pages
  • RNCOS E-Services Private Limited
1 of 5
The Renal Cell Carcinoma Drugs Market is Anticipated to Cross US$ 4 Billion by 2020

FEATURED COMPANIES

  • Amgen Inc.
  • AstraZeneca
  • Bayer AG
  • Bristol-Myers Squibb
  • Eli Lilly & Co.
  • F.Hoffmann-La Roche AG
  • MORE
Renal cell carcinoma, also called renal adenocarcinoma, is a disease in which malignant or cancerous cells are found in the lining of tubules in the kidney. There are many factors, like smoking, hypertension, unhealthy eating habits and family history, which increase the risk of occurrence of renal cell carcinoma. Various tests, like ultrasound, urine analysis, intravenous pyelogram, CT scan, MRI and biopsy, are available now-a-days that can help in early diagnosis of this disease. The drugs which are used for the treatment of the renal cell carcinoma include the likes of Sutent, Votrient, Inlyta and Nexavar among others. The latest addition to this lot is Opdivo by Bristol-Myers Squibb. Moreover, there are many more drugs in various phases of clinical trials, which will help in the growth of this market.

According to the report “Global Renal Cell Carcinoma Drugs Market 2020”, the renal cell carcinoma drugs market is anticipated to cross US$ 4 Billion by 2020. The report provides a detailed analysis of the market for these drugs. The report provides the current and forecasted market for renal cell carcinoma drugs.

Moreover, the report provides information and revenues of the major branded drugs in the market for this disease. The segmentation of renal cell carcinoma drugs market has been done in the report on the basis of different geographical regions. North America is accounted for the largest share of the renal cell carcinoma market. This high share was attributed to colossal patient pool, large number of commercially available drugs for the treatment of renal cell carcinoma, favourable healthcare insurance coverage, and impressive healthcare systems customized for the pharmaceutical sector. However, the Asia Pacific market is poised to witness the highest growth in coming years owing to improving healthcare facilities in the region coupled with rising patient pool.

It also highlights RCC drugs at various stages of clinical development. In addition, the report also provides insight about the major drivers and challenges, latest trends and developments, and strategic collaborations impacting the industry growth.

The later part of the report discusses some of the prominent players in the global renal cell carcinoma drug market. The market share analysis of these players is also provided in the report. Furthermore, a brief business overview of each player has been provided along with their business segments, product portfolios and recent developments. Moreover, analysis of their strengths and weaknesses has also been done. Overall, the report will prove as a complete source of knowledge and analysis for clients and potential investors.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Amgen Inc.
  • AstraZeneca
  • Bayer AG
  • Bristol-Myers Squibb
  • Eli Lilly & Co.
  • F.Hoffmann-La Roche AG
  • MORE
1. Analyst View

2. Research Methodology

3. Renal Cell Carcinoma - An Introduction

4. Drivers and Challenges
4.1 Drivers
4.1.1 Increasing Geriatric Population
4.1.2 Quick Diagnosis with Modern Imaging Techniques
4.1.3 Increasing Risk from Lifestyle Related Factors
4.1.4 Grants and Tax Credits
4.2 Challenges
4.2.1 High Cost
4.2.2 Lack of Disease History Awareness & Research Participants
4.2.3 Rising Patent Cliff

5. Renal Cell Carcinoma Drugs Market Overview

6. Major Branded Drugs
6.1 Sutent
6.2 Votrient
6.3 Afinitor
6.4 Nexavar
6.5 Inlyta
6.6 Avastin
6.7 Proleukin
6.8 Torisel
6.9 Opdivo

7. Market Segmentation By Geography
7.1 North America
7.2 Europe
7.3 Asia-Pacific

8. Renal Cell Carcinoma Drugs Pipeline

9. Trends and Developments
9.1 Positive Outcomes from Clinical Trials Driving RCC Market
9.2 ADCs - A Novel Treatment Option for RCC

10. Mergers and Acquisitions

11. Competitive Landscape

12. Key Players Analysis
12.1 Pfizer Inc.
12.2 F.Hoffmann-La Roche AG
12.3 Novartis
12.4 GlaxoSmithKline
12.5 Bayer AG
12.6 Bristol-Myers Squibb
12.7 Merck & Co., Inc.
12.8 AstraZeneca
12.9 Eli Lilly & Co.
12.10 Amgen Inc.

List of Tables
Table 8-1: Renal Cell Carcinoma Drugs Pipeline
Table 10-1: Mergers & Acquisitions in Renal Cell Carcinoma Drugs Market, 2013-2016
Table 11-1: Global - Major Renal Cell Carcinoma Drugs
Table 12-1: Pfizer Inc - Revenues by Business Segment (Billion US$), 2012, 2013 & 2014
Table 12-2: Pfizer Inc - Commercialized Renal Cell Carcinoma Drugs
Table 12-3: Pfizer Inc - Renal Cell Carcinoma Drugs Pipeline
Table 12-4: Roche - Revenue by Business Segments (Billion US$), 2013, 2014 & 2015
Table 12-5: Roche - Commercialized Renal Cell Carcinoma Drugs
Table 12-6: Roche - Renal Cell Carcinoma Drug in Pipeline
Table 12-7: Novartis - Revenue by Business Segments (Billion US$), 2012, 2013 & 2014
Table 12-8: Novartis - Commercialized Renal Cell Carcinoma Drugs
Table 12-9: Novartis - Renal Cell Carcinoma Drugs Pipeline
Table 12-10: GlaxoSmithKline - Revenue by Business Segments (Billion US$), 2012, 2013 & 2014
Table 12-11: GlaxoSmithKline - Commercialized Renal Cell Carcinoma Drugs
Table 12-12: GlaxoSmithKline - Renal Cell Carcinoma Drugs Pipeline
Table 12-13: Bayer AG - Revenue by Business Segments (Billion US$), 2012, 2013 & 2014
Table 12-14: Bayer AG - Commercialized Renal Cell Carcinoma Drugs
Table 12-15: Bristol Myers Squibb - Revenue by Business Segments (Billion US$), 2012, 2013 & 2014
Table 12-16: Bristol Myers Squibb - Commercialized Renal Cell Carcinoma Drugs
Table 12-17: Bristol Myers Squibb - Renal Cell Carcinoma Drugs Pipeline
Table 12-18: Merck & Co., Inc. - Revenue by Business Segments (Billion US$), 2012, 2013 & 2014
Table 12-19: Merck & Co., Inc. - Renal Cell Carcinoma Drugs Pipeline
Table 12-20: AstraZeneca - Revenue by Business Segments (Billion US$), 2012, 2013 & 2014
Table 12-21: AstraZeneca - Renal Cell Carcinoma Drugs Pipeline
Table 12-22: Eli Lilly & Co. - Revenue by Business Segments (Billion US$), 2012, 2013 & 2014
Table 12-23: Eli Lilly & Co. - Renal Cell Carcinoma Drugs Pipeline
Table 12-24: Amgen Inc. - Revenue by Business Segments (Billion US$), 2012, 2013 & 2014
Table 12-25: Amgen Inc. - Renal Cell Carcinoma Drugs Pipeline

List of Figures
Figure 4-1: Global - Population above 60 Years (Billion), 2013 & 2050
Figure 5-1: Global - Renal Cell Carcinoma Drugs Market (Billion US$), 2015-2020
Figure 6-1: Sutent - Global Revenue (Billion US$), 2011-2014
Figure 6-2: Votrient - Global Revenue (Billion US$), 2011-2014
Figure 6-3: Afinitor - Global Revenue (Billion US$), 2011-2014
Figure 6-4: Nexavar - Global Revenue (Billion US$), 2011-2014
Figure 6-5: Inlyta - Global Revenue (Billion US$), 2012-2014
Figure 6-6: Avastin - Global Revenue (Billion US$), 2011-2014
Figure 6-7: Proleukin - Global Revenue (Billion US$), 2012-2014
Figure 6-8: Torisel - Global Revenue (Billion US$), 2012 & 2013
Figure 7-1: Global - Renal Carcinoma Drugs Market by Geographies (%), 2015
Figure 7-2: North America - Renal Cell Carcinoma Drugs Market (Billion US$), 2015-2020
Figure 7-3: Europe - Renal Cell Carcinoma Drugs Market (Billion US$), 2015-2020
Figure 7-4: Asia-Pacific - Renal Cell Carcinoma Drugs Market (Billion US$), 2015-2020
Figure 11-1: Global - Share of Major Players in Renal Cell Carcinoma Drugs Market (%), 2015
Figure 12-1: Pfizer Inc - Breakup of Revenue by Geographies (%), 2014
Figure 12-2: Roche - Breakup of Pharmaceutical Division Revenue by Geographies (%), 2015
Figure 12-3: Novartis - Breakup of Revenue by Geographies (%), 2014
Figure 12-4: GlaxoSmithKline - Breakup of Revenue by Geographies (%), 2014
Figure 12-5: Bayer AG - Breakup of Revenue by Geographies (%), 2014
Figure 12-6: Bristol Myers Squibb - Breakup of Revenue by Geographies (%), 2014
Figure 12-7: Merck & Co., Inc. - Breakup of Revenue by Geographies (%), 2014
Figure 12-8: AstraZeneca - Breakup of Revenue by Geographies (%), 2014
Figure 12-9: Eli Lilly and Company - Breakup of Revenue by Geographies (%), 2014
Figure 12-10: Amgen Inc. - Breakup of Revenue by Geographies (%), 2014
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Amgen Inc.
  • AstraZeneca
  • Bayer AG
  • Bristol-Myers Squibb
  • Eli Lilly & Co.
  • F.Hoffmann-La Roche AG
  • MORE
ADCs - A Novel Treatment Option for RCC

Advancements in technology have helped in the development of novel drug molecules for the treatment of renal cell carcinoma. An example of one such type of drug molecules is ADCs. ADCs are monoclonal antibodies attached to biologically active drugs by chemical linkers with labile bonds. They allow sensitive discrimination between healthy and diseased tissue. Pharmaceutical companies are speeding up the development and commercialization of more of these ADCs as an alternative treatment option, which will help in the overall growth of renal cell carcinoma drug industry.

According to “Global Renal Cell Carcinoma Drugs Market 2020” report recently, a group of scientists at Agensys Inc. developed a novel ADC by the name of AGS16F. Clinical trials are indicating that AGS16F inhibited tumor growth. AGS16F localized to tumors, formed the active metabolite Cys-mcMMAF, induced cell cycle arrest and apoptosis, and increased blood levels of caspase-cleaved cytokeratin-18, a marker of epithelial cell death. Similarly, Agensys Inc. is also developing another ADC for the treatment of clear cell RCC and papillary RCC. The ADC, AGS-16M8F/AGS-16C3F, is being developed with the help of ADC technology in-licensed from Seattle Genetics. AGS-16M8F is a fully human IgG2k monoclonal antibody, conjugated to microtubule disrupting agent MMAF via a plasma-stable linker, which bind to ENPP3. After successful completion and satisfactory results from the phase II trials, this compound will be transitioned to Astellas’ development team who will conduct the Phase III studies and prepare and submit the NDA/BLA.

Another company, Seattle Genetics, is also developing a novel treatment option for renal cell carcinoma. This treatment option is by the name of SGN-CD70A. SGN-CD70A is a novel antibody-drug conjugate targeted to CD70 utilizing the company’s newest ADC technology. This ADC is currently under phase I clinical trial which have been designed to assess its safety and antitumor activity in patients suffering from renal cell carcin
Note: Product cover images may vary from those shown
5 of 5
- Amgen Inc.
- AstraZeneca
- Bayer AG
- Bristol-Myers Squibb
- Eli Lilly & Co.
- F.Hoffmann-La Roche AG
- GlaxoSmithKline
- Merck & Co., Inc.
- Novartis
- Pfizer Inc.

Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll